lcerative Colitis Therapeutics Market, Global, Prescription
Population, 2001-2009 64
Table 82: Ulcerative Colitis Therapeutics Market, Global, Prescription
Population, 2009-2016 64
Table 83: Ulcerative Colitis Therapeutics Market, Global, Usage Patterns,
2001-2009 65
Table 84: Ulcerative Colitis Therapeutics Market, Global, Usage Patterns,
2009-2016 66
Table 85: GERD Therapeutics Market, Global, Revenue ($m), 2001-2009 70
Table 86: GERD Therapeutics Market, Global, Revenue ($m), 2009-2016 70
Table 87: GERD Therapeutics Market, Global, Annual Cost of Treatment,
2001-2009 71
Table 88: GERD Therapeutics Market, Global, Annual Cost of Treatment,
2009-2016 71
Table 89: GERD Therapeutics Market, Global, Diseased Population,
2001-2009 72
Table 90: GERD Therapeutics Market, Global, Diseased Population,
2009-2016 72
Table 91: GERD Therapeutics Market, Global, Treatment Seeking Population,
2001-2009 73
Table 92: GERD Therapeutics Market, Global, Treatment Seeking Population,
2009-2016 73
Table 93: GERD Therapeutics Market, Global, Diagnosis Population,
2001-2009 74
Table 94: GERD Therapeutics Market, Global, Diagnosis Population,
2009-2016 74
Table 95: GERD Therapeutics Market, Global, Prescription Population,
2001-2009 75
Table 96: GERD Therapeutics Market, Global, Prescription Population,
2009-2016 75
Table 97: GERD Therapeutics Market, Global, Usage Patterns, 2001-2009 76
'/>"/>SOURCE MarketsandMarkets Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 Related biology technology :1.
Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation2.
ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs3.
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery4.
DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD5.
Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders6.
New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinsons Disease7.
Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program8.
TAP Pharmaceutical Products Inc. Files New Drug Application for TAK-390MR in Patients with Acid-Related Disorders9.
Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders10.
SleepQuest Raises Awareness of Sleep Disorders11.
S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders